Skip to main content
LAVA Therapeutics NV logo

LAVA Therapeutics NV — Investor Relations & Filings

Ticker · LVTX ISIN · NL0015000AG6 LEI · 724500HENIO3AVE6KA30 US Manufacturing
Open in API
Filings indexed 160 across all filing types
Latest filing 2021-05-28 Regulatory Filings
Country NL Netherlands
Listing US LVTX

About LAVA Therapeutics NV

https://www.lavatherapeutics.com/

LAVA Therapeutics NV is a clinical-stage immuno-oncology company that develops cancer therapies through its proprietary Gammabody® platform. This platform generates bispecific antibodies designed to engage and activate Vγ9Vδ2 (Vgamma9 Vdelta2) T cells, a unique and abundant subset of immune effector cells. The therapeutic approach aims to direct these T cells to tumors, leading to the selective killing of cancer cells and the stimulation of a broader, durable anti-tumor immune response. The company's focus is on creating treatments that complement natural tumor recognition and have the potential to enhance patient survival across various malignancies.

Recent filings

Filing Released Lang Actions
S-8
Regulatory Filings Classification · 100% confidence The document is a Form S-8 Registration Statement filed with the SEC, which is used to register securities to be offered under employee benefit plans such as stock option plans and employee stock purchase plans. The text includes detailed information about the securities to be registered, the plans under which they are offered, and legal and indemnification provisions. It is not a financial report, earnings release, or management discussion, but a regulatory filing related to securities registration. Therefore, it fits best under the category of Regulatory Filings (RNS). The document length and content confirm it is not a brief announcement or a report publication announcement.
2021-05-28 English
6-K
Interim / Quarterly Report Classification · 95% confidence The document is a Form 6-K filed by a foreign issuer, LAVA Therapeutics N.V., with the SEC. It references the issuance of unaudited condensed consolidated interim financial statements and associated management's discussion and analysis for the three months ended March 31, 2021. The document itself is a report of foreign issuer pursuant to SEC rules, containing interim financial data and MD&A. The length is 2762 characters, which is relatively short but contains substantive financial data and analysis for a quarterly period. Therefore, it fits the definition of an Interim / Quarterly Report (IR).
2021-05-20 English
SC 13D
Major Shareholding Notification
2021-04-08 English
SCHEDULE 13G
Major Shareholding Notification
2021-04-08 English
SC 13D
Major Shareholding Notification
2021-03-31 English
SC 13D
Major Shareholding Notification
2021-03-31 English

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.